IQVIA Holdings Inc. (IQV) – What Are Investment Firms Saying About This Stock?

IQVIA Holdings Inc. (NYSE:IQV) has received an average recommendation of “Moderate Buy” from the seventeen brokerages that are currently covering the company, MarketBeat reports. Three investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $276.00.

Several analysts recently issued reports on IQV shares. UBS Group assumed coverage on IQVIA in a report on Wednesday, September 30th. They set a “buy” rating and a $345.00 price objective for the company. TD Cowen boosted their target price on shares of IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Royal Bank Of Canada boosted their target price on shares of IQVIA from $247.00 to $319.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 29th. Deutsche Bank Aktiengesellschaft set a $240.00 price objective on IQVIA in a report on Thursday, July 9th. Finally, Morgan Stanley increased their price target on shares of IQVIA from $240.00 to $270.00 and gave the stock an “equal weight” rating in a research report on Thursday, September 17th.

Insider Transactions at IQVIA

In other news, insider W. Richard Staub sold 5,500 shares of the firm’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $232.68, for a total value of $1,279,740.00. Following the completion of the sale, the insider directly owned 13,312 shares in the company, valued at approximately $3,097,436.16. This trade represents a 29.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Bhavik Patel sold 1,855 shares of the business’s stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $235.27, for a total transaction of $436,425.85. Following the completion of the transaction, the insider directly owned 1,348 shares of the company’s stock, valued at approximately $317,143.96. This represents a 57.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 15,581 shares of company stock valued at $3,796,021. 1.70% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Apella Capital LLC grew its holdings in shares of IQVIA by 4.7% in the third quarter. Apella Capital LLC now owns 1,235 shares of the medical research company’s stock valued at $319,000 after purchasing an additional 55 shares in the last quarter. Breakwater Capital Group grew its stake in shares of IQVIA by 3.2% during the second quarter. Breakwater Capital Group now owns 2,073 shares of the medical research company’s stock valued at $401,000 after buying an additional 64 shares during the last quarter. Fortitude Family Office LLC increased its stake in IQVIA by 17.2% in the third quarter. Fortitude Family Office LLC now owns 443 shares of the medical research company’s stock worth $119,000 after purchasing an additional 65 shares during the period. First Growth Capital LLC increased its stake in IQVIA by 3.2% in the 1st quarter. First Growth Capital LLC now owns 2,173 shares of the medical research company’s stock worth $375,000 after buying an additional 68 shares during the period. Finally, Chicago Partners Investment Group LLC raised its stake in shares of IQVIA by 1.5% during the first quarter. Chicago Partners Investment Group LLC now owns 4,635 shares of the medical research company’s stock valued at $812,000 after acquiring an additional 70 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Down 0.4%

IQV stock opened at $265.72 on Tuesday. The company’s 50 day simple moving average is $261.23 and its 200-day simple moving average is $213.85. The firm has a market capitalization of $43.74 billion, a P/E ratio of 32.97, a P/E/G ratio of 2.32 and a beta of 1.17. IQVIA has a 52-week low of $154.50 and a 52-week high of $277.40. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping the consensus estimate of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%. The business had revenue of $4.37 billion during the quarter, compared to analysts’ expectations of $4.30 billion. During the same quarter last year, the firm posted $2.81 earnings per share. IQVIA’s revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, equities research analysts anticipate that IQVIA will post 11.56 EPS for the current year.

About IQVIA

IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.

Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.